OpenAlex
PricingAboutJobs
Log inGet started
Work

Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors

HTML

Year: 2010
Type: article
Source: Clinical Cancer Research
DOI: 10.1158/1078-0432.ccr-10-0748
Authors: José Baselga, Andres Cervantes, Erika Martinelli, Isabel Chirivella, Klaas Hoekman, Herbert I. Hurwitz, Duncan I. Jodrell, Paul Hamberg, Esther Casado, Paul Elvin, Alan Swaisland, Renee Iacona, Josep Tabernero
Institutions: Universitat Autònoma de Barcelona, Universitat de València, Edinburgh Cancer Research, Duke Medical Center, Vall d'Hebron Hospital Universitari, Duke University Hospital, Vall d'Hebron Institute of Oncology, AstraZeneca (United Kingdom)
Language: English

Topic: Cancer Mechanisms and Therapy
Subfield: Cancer Research
Field: Biochemistry, Genetics and Molecular Biology
Domain: Life Sciences
Keywords: saracatinib, AZD0530, Src kinase inhibitor, solid tumors, pharmacokinetics, maximum tolerated dose, drug safety and tolerability, dose accumulation, advanced cancer
SDG: Good health and well-being

Open Access status: closed

Funder: AstraZeneca
OpenAlex ID: W2127283584
FWCI: 2.767
Cites: 18
Cited by: 118
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Subscribe
Supporters
Legal
Privacy
Accessibility
Terms
Security